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Objectives: this study examined the effect of immune modulation therapy (IMT) on claudication distances.
Materials and methods: a double-blind placebo controlled trial was performed on patients with disabling intermittent
claudication with randomisation stratified for short and long distance IC. For IMT, following exposure to UV light,
oxidisation and 42.5C, 10 ml of citrated autologous blood was administered by intra-muscular injection. One course
consisted of 6 injections in 3-weeks followed by 3-weeks rest. Patients received 2, 3 or 4 courses depending on response. The
primary end-point was the number of responders (> 50% increase in initial claudication distance (ICD)) in each group.
Secondary end-points included percentage changes in ICD and change in quality of life.
Results: at week 24, there were more responders in the IMT group (20/31, 65%) compared to placebo (16/39, 41%)
(p 0.06). In the subgroup of short distance claudicants this difference reached significance (IMT 17/26, 65%) (Placebo
12/33, 36%) (p 0.04). The median increase in ICD was significantly greater in the IMT group (81%) compared to placebo
(44%, p 0.04). These results were supported by quality of life measurements.
Conclusions: IMT is a safe and apparently effective treatment for patients with short distance claudication.
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Intermittent claudication (IC) is the most common
symptom of peripheral arterial occlusive disease
(PAOD), affecting between 1±9% of the population,
increasing with age.1,2 Patients with IC can be severely
impaired in their ability to perform daily activities3
and have a lower quality of life.4 Current treatments
include risk factor modification, exercise therapy, bal-
loon angioplasty, medication and surgery.
Vascular physicians have long advised patients
with IC to `` stop smoking and keep walking''.5 There
is longstanding evidence that a well structured super-
vised exercise programme can be of benefit,6±8 how-
ever, patient compliance can be poor.9 Balloon
angioplasty is a popular choice of treatment, but not
all patients are suitable and even with good patient* Please address all correspondence to: C. McGrath, Vascular
Research Sister, Vascular Studies Unit, Level 7, Bristol Royal
Infirmary, Marlborough Street, Bristol, BS2 8HW, U.K.
1078±5884/02/050381  07 $35.00/0 # 2002 Elsevier Science Ltd. Alselection, there is technical failure to recanalise and/or
dilate a lesion in 10±20% of cases.10 Up to 2% will
require surgery, thrombolysis, embolectomy or repair
of false aneurysm and there are risks of amputation
(0.3%) and death (0.17%).10 Surgical reconstruction is
more durable than angioplasty but again there are
significant risks of early and late complications. In
consequence, operations are reserved for patients
with more severe symptoms.9 Many pharmacological
treatments have been tried for the treatment of IC,
though without major benefit.11
Immune modulation therapy (IMT) is a new thera-
peutic approach for treating IC and involves the
administration of autologous blood components
following their ex vivo processing by exposure to ther-
mal and oxidative stress.12 Both open-label and con-
trolled clinical studies have indicated that IMT may be
helpful in relieving symptoms of claudication.13 The
exact mechanism of therapy is under investigation.
However, pre-clinical and clinical data support a role
for IMT in improving endothelial function13 and inl rights reserved.
382 C. McGrath et al.reducing levels of inflammation in pre-clinical models
of atherosclerosis14 and Th1-driven models of
inflammation.15,16
Patients with PAOD have a high prevalence of
coronary artery atherosclerosis,18 suggesting wide-
spread vascular disease.19 Endothelial dysfunction
has been demonstrated in the brachial artery of
patients with known coronary artery disease and dia-
betes.17 Endothelial dysfunction may be, in part, due
to inflammation caused by chronic ischaemia and
reperfusion.20 IMT reduces inflammatory responses
in animal models16 and protects against injury follow-
ing ischaemia and reperfusion.21
Improvements in endothelial function following
IMT have been demonstrated by an increased vasodi-
latory response to acetylcholine in rabbit arterial ring
preparations.13 This improvement in vasodilatory
function is further supported by the detection of an
increase in endothelium dependent skin blood flow in
patients with severe Raynaud's syndrome following a
course of IMT.22 IMT also increases the rate of reco-
very of skin blood flow following occlusion in patients
with PAOD.13
Pre-clinical work in LDL receptor deficient mice
showed that aortic lipid deposition, was reduced
following treatment with IMT, compared to untreated
mice.23 The authors proposed that as this study
demonstrated reduction in the development of athero-
sclerosis in its early stages, in a model of human
familial hypercholesterolaemia, IMT may induce
regression of established atherosclerotic lesions.
Thus, in patients suffering from IC as a result of
PAOD, IMT could stem the progression of atheroscler-
osis, reduce inflammatory responses and improve
endothelial function, leading to increased microvas-
cular blood flow in the claudicating muscle and
improved walking distance.
Patients and Methods
This randomised double-blind placebo-controlled par-
allel group study was performed in two centres in the
U.K.; Department of Vascular Surgery, Bristol Royal
Infirmary and Department of Medicine, Ninewells
Hospital and Medical School, Dundee. Approval to
conduct the study was obtained from the Local
Research Ethical Committees and the study was con-
ducted in accordance with the Declaration of Helsinki
and International Committee for Harmonisation Good
Clinical Practice guidelines. All patients gave written
informed consent prior to participation.
Between May 1998 and September 2000, 92 patients
were consented to participate. Each centre recruitedEur J Vasc Endovasc Surg Vol 23, May 200246 patients. All entrants to the trial had stable IC of at
least three months duration. A clinical diagnosis of
atheromatous occlusive disease was supported by a
resting ankle brachial pressure index of less than 0.8 in
either or both legs. The distances walked before onset
of pain, initial claudication distance (ICD) and before
stopping due to pain, absolute claudication distance
(ACD) were assessed using a standardised constant
load treadmill test (2 km/h, 10% incline). At entry, a
minimum of 2 and maximum of 4 treadmill tests were
performed and the ICD of the most recent 2 tests had
to have a variance of less than 25%. Exclusions at this
stage included: rest pain, ulcers and/or gangrene;
diminished walking performance for any reason
other than arterial disease (e.g. shortness of breath,
angina); vascular surgery or angioplasty within
3 months; anticipated vascular intervention during
course of study; myocardial infarction within
6 months; severe concomitant diseases including
haemorrhagic and coagulation disorders; concomitant
use of vasoactive therapies such as prostacyclin
analogues, nicorandil, cinnarazine, naftidrofuryl,
nicotine acid derivatives, oxpentifylline and thymox-
amine; use of immunosupressants, cytotoxic agents,
including systemic corticosteroids, photosensitising
agents and standard unfractionated heparin. ACE
inhibitors, nitrates and calcium channel blockers
were permitted provided that drug and dosage had
remained stable in the 3 months prior to the study.
Aspirin was permitted. Concomitant drug therapy
remained unchanged during the study where feasible.
Patients had previously received advice on risk factors
such as smoking cessation, diet and exercise as part of
their normal management. No further advice was
given during the study period.
Randomisation to active agent or placebo was
computer generated and stratified for diabetes and
walking ability to ensure homogeneity between treat-
ment groups. Patients were classified as being either
short distance claudicants, ACD less than 100 m, or
long distance claudicants, ACD between 100 m and
300 m. Forty-three were randomised to receive IMT
and 49 placebo.
For patients receiving IMT, a 10 ml aliquot of
venous blood was drawn from the antecubital fossa,
into 2 ml of anti-coagulant sodium citrate solution,
3.8% and placed in a disposable vessel (VC7002, Vaso-
gen Inc. Toronto, Canada). It was then inserted into
the Vasogen VC7001 medical device. Within the device
the blood was exposed to controlled levels of UV light
(wavelength: 253.7 nm), oxidative stress (a gas mixture
of medical oxygen containing 14.5 1.0 mg/ml
of ozone, at a flow rate of 240 24 ml/min) and
thermal stress (42.5 1.0C), for a period of 3 min.
Treatment of IC with Immune Modulation Therapy 383Following an injection of local anaesthetic 10 ml of the
treated blood was administered to the patient by intra-
muscular injection into the upper gluteal region. Simi-
larly a 10 ml blood sample was collected from patients
allocated to receive placebo. However, this sample
was discarded and a 10 ml intra-muscular injection
of warm sterile saline administered, also following
local anaesthetic. In order to maintain the blindness
of the process, there were two investigators. One was
responsible for handling the blood samples and
administering injections, whilst the other performed
the venepunctures and study assessments. The
patients were also blinded during treatments. Patients
received between 12 and 24 injections of either IMT
treated autologous blood or placebo. After receiving
12 injections, non-responders (as judged by a less than
50% improvement in ICD during treadmill testing)
received an additional 6 injections, which could be
repeated again if no response was achieved.
Treadmill tests were performed at baseline and at
3 and 9 weeks following each course of treatment.
Quality of life was assessed using the Short Form 36
(SF-36) at the start and finish of the study.
The primary end-point was whether a claudicant
responded, as defined by a greater than 50% increase
in ICD over baseline. The number of responders in
each treatment group was compared using the Fisher's
exact test. Assuming a 10% placebo response rate,
40 evaluable patients in each treatment group were
needed to detect a 30% difference in response rate
between treatment groups with a 90% power and 5%
level of significance (p5 0.05).
The secondary end-points were changes in ICD and
ACD. These data were expressed as percentage
increase from baseline. The SF36 quality of life ques-
tionnaires were scored, coded, summed and trans-
formed. The results for each health domain as well
as the standardised physical and mental components
were compared for treatment effect. Analysis for
safety was performed on adverse events using the
Coding System Thesaurus for Adverse Reaction
Terms (COSTART). Each event was coded into one of
the following categories; body as a whole, cardiovas-
cular system, digestive system, haemic and lymphatic
systems, metabolic and nutritional disorders, musculo-
skeletal system, nervous system, respiratory system,
skin and appendages, special senses, urogenital tract.
The occurrence rate and severity for each category
was then compared between treatment groups.
Following examination for prevalence of normal
distributions, parametric data (age, weight, height,
blood pressure, ankle brachial pressure index) were
summarised as means and compared using the inde-
pendent t-test, whilst non-parametric data (durationof symptoms, ICD and ACD, quality of life and safety)
were summarised as medians and analysed using
the Mann±Whitney U-test. Results were considered
significant at the 5% level (p5 0.05).
The design of the trial was such that if a patient
`` responded'' then subsequently deteriorated they
were considered to have reached an end-point and
terminated the study. For this reason, along with
other patients lost to follow-up, the number of
patients in the study decreased over time (Fig. 1).
Results
Of the 92 patients enrolled in the study, 7 patients
were excluded from analysis prior to unblinding due
to major protocol violations (Fig. 1) during the first
12-week period. This left 85 patients in the intention-
to-treat (ITT) population. The randomised distribution
of these patients is given in Table 1. At baseline there
were no significant differences between groups in
baseline demographic and efficacy characteristics
(Table 2).
At week 24, after all treatments had been adminis-
tered, intention to treat analysis of the primary end-
point showed a greater number of responders in the
IMT group (20/31, 65%) compared to placebo (16/39,
41%) which approached statistical significance
(p 0.06, Fisher's exact test). In the subgroup of
patients with short distance claudication there was a
significantly greater number of responders in the IMT
group (17/26, 65%) compared to placebo (12/33, 36%),
(p 0.04, Fisher's exact test).
The median ICD and ACD results for the ITT popu-
lation are given in Table 3. At week 24, median ICD
had increased by 81% in the IMT group compared to
44% in the placebo group (p 0.04, Mann±Whitney
U-test). At the same time-point, median ACD also
increased in favour of IMT, however, this did not
reach statistical significant (IMT 50%, placebo 30%,
p 0.07 Mann±Whitney U-test).
Quality of life at the end of the study, as measured
by the standardised physical component (Table 4) was
significantly better in the IMT treated group com-
pared to the placebo group (p 0.041, Mann±Whitney
U-test). This was predominantly due to a significant
difference in favour of IMT in the physical role do-
main (p 0.03, Mann±Whitney U-test). The pain index
and vitality domains also improved significantly over
time for the IMT group (p 0.03, Wilcoxon t-test) how-
ever the difference between groups did not reach stat-
istical significance (p 0.06, Mann±Whitney U-test).
The IMT treated group scored significantly higher in
the mental health index domain compared to placeboEur J Vasc Endovasc Surg Vol 23, May 2002
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Table 1. Randomisation distribution, ITT data set.
Stratum Treatment
Baseline ACD Diabetes
Yes/No
Placebo
(%)
IMT
(%)
Total
(%)
5100 m Yes 5 (11) 5 (13) 10 (12)
>100 m Yes 1 (2) 0 (0.0) 1 (1)
5100 m No 34 (74) 29 (74) 63 (74)
>100 m No 6 (13) 5 (13) 11 (13)
46 (100) 39 (100) 85 (100)
Table 2. Baseline demographic and efficacy characteristics, ITT
data set.
Randomisation
Placebo
(n 46)
IMT
(n 39)
Gender (male:female) 24 : 22 25 : 14
52% : 48% 64% : 36%
Race ± Caucasian (n) 46 39
Age (mean) 68 68
Weight (kg) (mean) 74 76
Height (cm) (mean) 165 168
Current or past smoker (n) 36 (78%) 31 (80%)
Diabetes (n) 6 (13%) 5 (13%)
Systolic BP (mean) 148 159
Diastolic BP (mean) 76 77
Duration of Fontaine
stage II (months)
Group: ACD 20±99 mm
(median, IQ range)
37 (16±62) 42 (24±99)
Group: ACD 100±300 m
(median, IQ range)
60 (36±108) 60 (35±114)
Previous treatment for
PAOD (n) (%)
23 (50%) 18 (46%)
Intake of Aspirin (n) (%) 42 (54%) 35 (46%)
ICD (median, IQ range) 33 (25±38) 35 (23±52)
ACD (median, IQ range) 56 (46±75) 65 (44±92)
Lowest ABPI (mean s.d.) 0.57 (0.13) 0.53 (0.13)
Table 3. Median ICD and ACD, ITT data set.
Placebo (n 46) IMT (n 39) Mann±Whitney
U-test
Median (Inter-
quartile range)
Median (Inter-
quartile range)
p value
ICD (m)
Baseline 33 (23±46) 33 (22±53) 0.825
Week 6 38 (21±62) 46 (29±67) 0.250
Week 12 41 (23±60) 54 (27±73) 0.149
Week 18 51 (22±72) 56 (36±83) 0.173
Week 24 47 (30±76) 69 (38±93) 0.039
Week 30 48 (27±74) 76 (37±97) 0.089
ACD (m)
Baseline 56 (43±73) 65 (45±89) 0.338
Week 6 55 (42±91) 75 (54±111) 0.193
Week 12 71 (47±108) 86 (60±141) 0.127
Week 18 73 (46±139) 112 (58±143) 0.143
Week 24 78 (50±131) 113 (64±163) 0.069
Week 30 82 (50±129) 116 (64±163) 0.111
 Significant 0.05 level.
Table 4. Quality of life, ITT data set.
End of study Placebo (n 46) IMT (n 39)
Median
(IQ range)
Median
(IQ range)
Role ± physical 25 (0±75) 75 (25±100)
Mental health index 76 (66±84) 84 (72±92)
Standardised physical component 36 (27±43) 40 (35±48)
 Significant at 0.05 level.
Treatment of IC with Immune Modulation Therapy 385group (p 0.02, Mann±Whitney U-test) although this
was not reflected in the standardised mental compo-
nent (p 0.2, Mann±Whitney U-test). No significant
differences were noted in the general health percep-
tion, social functioning, emotional role and health
transition domains.
Adverse Events
In total 518 adverse events were reported during the
study. All except a small minority were insignificant.
A preponderance of events (IMT 43%, placebo 46%)
occurred in the `` body as a whole category'' with
symptoms of influenza being the main complaint.
The remaining 288 events were evenly split between
the other 10 COSTART categories and were also even-
ly distributed between treatment groups. The mostsevere cardiac event reported was angina pectoris,
but again there was no difference in the occurrence
rate or severity between IMT and placebo. No signifi-
cant irregularities were noted in laboratory para-
meters. Two patients died during the study, one of
peritonitis and pneumonia (placebo) and a second of
a perforated duodenum and acute liver failure, sec-
ondary to past alcoholism (IMT). Neither death was
related to treatment.
Discussion
The Transatlantic Inter-Society Consensus (TASC)
recommends that to be valid, a trial assessing a new
treatment for IC must have parallel groups, be rando-
mised and double blind. As the symptom under scru-
tiny is claudication, change in walking performance
should be a primary end-point and assessed objec-
tively. Constant-load or graded treadmill testing is an
acceptable means to do this. Quality of life should be
assessed using a questionnaire validated for this
group of patients.11 Although the TASC report was
not available at the time this study was designed it
complies well with the recommendations.Eur J Vasc Endovasc Surg Vol 23, May 2002
386 C. McGrath et al.In this study the baseline demographic data is typ-
ical for a group of patients suffering with IC, with
more males than females, increasing age, a proportion
of diabetics and a high occurrence of current or past
smoking. The results consistently demonstrate greater
symptomatic improvement in the IMT group com-
pared to placebo. Potential mechanisms for these
improvements were not directly studied here but sup-
port the hypothesis that treatment with IMT may
result in increased microvascular blood flow through
improved endothelial function and reduced inflam-
matory responses. It is likely that ability of IMT to
reduce atherosclerotic progression had little effect on
the outcomes studies here. However, the benefits of
this effect on long term mortality and morbidity could
be great.
Endothelium dysfunction occurs in patients with
diabetes and arterial disease. It is possible that this
damage may become too severe for IMT to be effec-
tive. Thus a poorer outcome may be expected from
patients with severe arterial disease, with diabetes or
with both. When there is a possibility that the treat-
ment may be effective in only a subgroup randomisa-
tion stratification is recommended to ensure
comparability between the active and control
groups.11 The relatively small sample size of this
study could have lead to an unequal number of
patients with severe arterial disease, diabetes or both
in the treatment groups; however, this was successfully
overcome by stratifying the randomisation. Due to
the small number if diabetic patients recruited, pos-
sibly a reflection of the small sample size, it was not
appropriate to analyse this group separately thus
examining the response to IMT in these patients
alone is beyond the scope of this study. However, in
contrast to exercise24±29 and Cilostazol trials30±32 the
majority of patients recruited here were short distance
claudicants. The increased severity of IC in the study
population can be attributed to patients being
recruited from two specialist units. Although sub-
group analysis of this population was not pre-planned
and must therefore be considered exploratory, the
improvements seen in the IMT treated short distance
claudicants do not support the hypothesis that IMT
may be less effective in patients more severe disease.
Alternatively when endothelium damage is severe
and widespread the potential for systemic improve-
ment and thus symptomatic improvement may be the
same or greater.
In this study IMT was associated with an increase in
ICD that exceeded the typical increase of 32% seen in
similar pharmacological studies.33 Trials of supervised
exercise however, report greater improvements,
170%34 though compliance is often a problem. GivenEur J Vasc Endovasc Surg Vol 23, May 2002the potential systemic and symptomatic improve-
ments resulting from treatment with IMT a combin-
ation of this therapy and exercise may be advised.
The overall physical improvement in quality of life
reflects the increases seen in walking distance. IMT
had no significant effect on the standardised mental
component although the placebo group deteriorated.
This may be a reflection of placebo patients' having
a higher level of dissatisfaction due to less of an
improvement in walking ability.
In accordance with the International Committee for
Harmonisation Good Clinical Practise Guidelines, any
and every change in a patient's condition was pro-
spectively recorded as an adverse event, whether or
not it was considered to be related to the study. The
number of adverse events recorded demonstrates
rigorous and meticulous data collection. Subsequent
analysis using the COSTART system raised no con-
cerns about the safety of IMT.
Conclusion
In this study IMT produced significant increases in
walking distances in comparison to the placebo
group and these increases were reflected in improve-
ments in the patients' quality of life. IMT is a safe and
apparently effective treatment for patients with
disabling IC.
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